Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Signal-averaged electrocardiography

A A Graham1, H Handelsman

  • 1U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, Rockville, Maryland, USA.

Health Technology Assessment
|November 6, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Cryosurgery for recurrent prostate cancer following radiation therapy.

Health technology assessment·2002
Same author

Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction.

Journal of the American College of Cardiology·2001
Same author

Dysrhythmia hazard after hospitalization for myocardial infarction: two ECG prognostic methods compared.

Journal of electrocardiology·2001
Same author

US Food and Drug Administration: adverse event reporting.

CRNA : the clinical forum for nurse anesthetists·1998
Same authorSame journal

Lung-volume reduction surgery for end-stage chronic obstructive pulmonary disease.

Health technology assessment·1996
Same author

Haematopoietic stem-cell transplantation in multiple myeloma.

Cancer treatment reviews·1996
Same journal

18F-labeled 2-deoxy-2-fluoro-D-glucose positron-emission tomography scans for the localization of the epileptogenic foci.

Health technology assessment·1998
Same journal

Bone densitometry: patients receiving prolonged steroid therapy.

Health technology assessment·1996
Same journal

Bone densitometry: patients with end-stage renal disease.

Health technology assessment·1996
Same journal

Plethysmography: safety, effectiveness, and clinical utility in diagnosing vascular disease.

Health technology assessment·1996
See all related articles

Signal-averaged electrocardiography (SAECG) detects ventricular late potentials, aiding risk assessment for sudden cardiac death. While promising, its standalone utility requires further proof, especially in diverse patient groups.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Diagnostics

Background:

  • Ventricular late potentials (VLPs) detected by signal-averaged electrocardiography (SAECG) indicate increased risk of ventricular tachyarrhythmias and sudden cardiac death.
  • SAECG aims to non-invasively identify high-risk patients, potentially avoiding invasive procedures.

Purpose of the Study:

  • To evaluate the clinical utility and diagnostic accuracy of SAECG for risk stratification in cardiac patients.
  • To assess the effectiveness of SAECG, alone and in combination with other tests, in predicting adverse cardiac events.

Main Methods:

  • Computerized analysis of standard surface electrocardiogram segments to detect subtle electrical impulses (VLPs) following the QRS complex.
  • Review of existing data on SAECG performance, including sensitivity, specificity, and predictive values in various patient populations.

Related Experiment Videos

  • Consideration of ongoing randomized clinical trials for future evidence.

    • Main Results:

    • SAECG demonstrates high negative predictive values but poor positive predictive values and variable sensitivity/specificity in patients with cardiomyopathy or post-myocardial infarction.
    • Combining SAECG with other cardiac function tests shows superior risk assessment compared to single-test approaches.
    • Clinical utility is established for SAECG combined with other tests in post-acute myocardial infarction patients.

    Conclusions:

    • The standalone diagnostic value of SAECG as a risk indicator is not yet definitively proven.
    • SAECG shows clinical utility when integrated with other standard risk assessment tools, particularly in post-myocardial infarction populations.
    • Further research and data from ongoing trials are necessary to establish the broader benefits of SAECG across different patient groups.